title: [Immunotherapy in lung cancer: checkpoint inhibitors].
abstract: Monoclonal antibodies against the PD-1 receptor or its ligands result in a recovery of T cell responses against tumor antigens. Nivolumab is the first antibody that has been approved in lung cancer. This mode of action is very intersting, especially because of long term responses and the moderate toxicity.
authors.affiliation: Thoraxonkologie, Klinik für Innere Medizin V, Pneumologie, Allergologie, Beatmungs- und Umweltmedizin, Universitätsklinikum des Saarlandes.
authors.forename: Thomas
authors.initials: T
authors.lastname: Wehler
authors.affiliation: III. Medizinsche Klinik und Poliklinik, Schwerpunkt Hämatologie, Internistische Onkologie und Pneumologie, Universitätsmedizin Mainz und Universitäres Centrum für Tumorerkrankungen (UCT) Mainz.
authors.forename: Beatrice
authors.initials: B
authors.lastname: Wehler
authors.affiliation: Onkologische Gemeinschaftspraxis, Schneiderstr. 12, 67655 Kaiserslautern.
authors.forename: Ingo
authors.initials: I
authors.lastname: Stehle
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D017277:Drug Approval; D005858:Germany; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000951:Antigens, Neoplasm; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C000594389:atezolizumab; C582435:pembrolizumab